Clinical analysis of 125Ⅰ brachytherapy alone for 24 recurrent parotid gland carcinoma / 中华放射医学与防护杂志
Chen ZHOU; Shuming LIU; Yan SHI; Mingwei HUANG; Lei ZHENG; Xiaoming LYU; Jie ZHANG; Jianguo ZHANG.
Chinese Journal of Radiological Medicine and Protection
; (12): 447-450, 2017.
Artículo
en Zh
| WPRIM | ID: wpr-621002
Objective To evaluate the efficacy of 125Ⅰ brachytherapy alone for the treatment of recurrent parotid gland carcinoma.Methods Recurrent parotid gland carcinoma patients (n =24) treated by 125Ⅰ brachytherapy alone between 2006 and 2013 at Peking University Hospital of Stomatology were enrolled in this retrospective study.All patients underwent surgery or radiotherapy.The local control rate,survival rate,and side effects were evaluated.Results The median follow-up time was 21 months (range,4-59 months).Among the 24 patients,6 had local failure and 10 died during the follow-up period.The 1-and 3-year overall survival rates,progression-free survival rates,local control rates were 74.8％ and 39.3％,74.8％ and 31.5％,82.0％ and 69.4％,respectively.No grade 3 or over radiation injury was found.Conclusions 125Ⅰ seed brachytherapy alone could provide an ahernative treatment method for inoperable recurrent parotid gland carcinoma patients.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados